Top FDA Drug Evaluation Chief Richard Pazdur Retires Amid Turmoil
The U.S. Food and Drug Administration announced that Richard Pazdur will retire just weeks after being elevated to lead drug evaluation, a move that intensifies scrutiny of the agency at a fraught moment. The abrupt exit follows reporting that raised questions about the legality and safety of a newly promoted fast approval pathway and highlights risks to patient safety and regulatory stability.
Richard Pazdur, a veteran oncology regulator who was named head of the Food and Drug Administration office responsible for drug evaluation in November, said he would retire, Reuters reported on December 2, 2025. His departure came barely weeks after the appointment and follows reporting that flagged internal concerns about the legality and safety of a fast approval pathway the agency has been promoting.
Pazdur had led the FDA oncology office for many years and was widely respected in research and clinical communities for his role overseeing cancer drug reviews. His rapid decision to step down from the broader drug evaluation post compounds uncertainty at the agency as leadership turnover continues under U.S. Health Secretary Robert F. Kennedy Jr. The agency said it respected Dr. Pazdur's decision and honored his long service.
The exit arrives amid broader turmoil that has drawn attention from Congress, patient groups, and public health experts worried about both the process and the outcomes of medical product regulation. Reporting by Reuters and STAT alleged the agency moved to expand and elevate a fast approval pathway despite internal questions about whether the pathway complied with legal requirements and whether it adequately protected patient safety. Those concerns, coupled with rapid leadership change, raise the prospect of delays and inconsistency in review decisions that could affect patients waiting for new treatments.
For communities that disproportionately bear the burden of disease, regulatory upheaval can translate into real world harms. Oncology patients, many of whom depend on predictable timelines for clinical trial progress and approval decisions, face heightened anxiety when the staff and structures that oversee those reviews are in flux. Communities of color and low income communities that already experience access barriers may be most vulnerable if regulatory missteps lead to approvals that are later questioned or to stalled reviews that limit access to promising therapies.
The agency now faces several immediate policy and operational challenges. Internally, morale and retention among career reviewers could suffer, undermining the continuity of expertise needed to assess complex safety and efficacy data. Externally, industry stakeholders may reassess engagement strategies, and patient advocacy organizations are likely to press for clearer commitments around transparency, independent oversight, and evidence standards.
The change also magnifies long running debates about the balance between speeding access to drugs and ensuring that approvals rest on solid evidence. Fast approval pathways can be valuable for serious conditions with no effective treatments, yet they require rigorous post market surveillance and enforcement to guard against exposing vulnerable patients to ineffective or unsafe products. Critics argue that shortcuts without adequate safeguards can exacerbate health inequities by delivering uncertain therapies to those with the least ability to absorb risk.
As the agency prepares to name a successor, policymakers and public health leaders will be watching how the FDA reasserts institutional norms and safeguards. Restoring confidence will demand transparent explanations of the pathway concerns that surfaced in recent reporting, clear plans to bolster review capacity, and renewed emphasis on protecting patients and underserved communities as central criteria of regulatory decision making.
